Literature DB >> 17499773

Sacral neuromodulation for nonobstructive urinary retention--is success predictable?

Meidee Goh1, Ananias C Diokno.   

Abstract

PURPOSE: We investigated whether there are factors which can predict successful stage II (permanent) sacral nerve stimulator (InterStim) implantation for patients with nonobstructive urinary retention.
MATERIALS AND METHODS: We retrospectively reviewed our sacral neuromodulation database from January 1, 1999 to January 1, 2006. A total of 29 patients were referred to the William Beaumont Hospital Department of Urology for nonobstructive urinary retention. All patients completed a 3-day voiding log followed by test stimulation. Patients underwent test stimulation for a 2-week trial period. Those who experienced 50% improvement in void volume and/or catheterization frequency subsequently underwent permanent implantation. We reviewed patient charts with respect to age, sex, duration of retention, underlying diagnosis for retention and voiding ability.
RESULTS: Of the 29 patients 15 were men and 14 were women. Mean patient age was 58.8+/-16 years (range 18 to 82). The mean age of the men in the study was 55.5+/-18 years while the mean age of the women was 62.3+/-14 years. Although all the patients performed intermittent self-catheterization 18 were able to void (more than 50 cc per void). The remaining 11 patients had minimal (50 cc or less) or no ability to void. Of the 18 patients who were able to void 12 (67%) underwent successful permanent implantation. However, voiding improved after test stimulation in only 2 of the 11 patients (18%) who had been unable to void. This difference was statistically significant (p=0.02) and suggests that pre-implantation ability to void can predict success of test stimulation.
CONCLUSIONS: Patient ability to void predicts success of first stage test stimulation. Although we would still offer a trial of sacral neuromodulation to those with nonobstructive urinary retention and the inability to void, this study would allow better counseling regarding the likelihood of successful outcome.

Entities:  

Mesh:

Year:  2007        PMID: 17499773     DOI: 10.1016/j.juro.2007.03.058

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  Sacral nerve stimulation in the elderly.

Authors:  Tomas L Griebling
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

Review 2.  Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.

Authors:  Samina Tahseen
Journal:  Int Urogynecol J       Date:  2018-01-04       Impact factor: 2.894

3.  Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women.

Authors:  Tajnoos Yazdany; Narender Bhatia; John Nguyen
Journal:  Int Urogynecol J       Date:  2011-07-28       Impact factor: 2.894

4.  National trends in the usage and success of sacral nerve test stimulation.

Authors:  Anne P Cameron; Jennifer T Anger; Rodger Madison; Christopher S Saigal; J Quentin Clemens
Journal:  J Urol       Date:  2011-01-19       Impact factor: 7.450

Review 5.  Sacral nerve stimulation to treat nonobstructive urinary retention in women.

Authors:  Craig V Comiter
Journal:  Curr Urol Rep       Date:  2008-09       Impact factor: 3.092

6.  Predictive Factors in Sacral Neuromodulation: A Systematic Review.

Authors:  Ranjana Jairam; Jamie Drossaerts; Tom Marcelissen; Gommert van Koeveringe; Desiree Vrijens; Philip van Kerrebroeck
Journal:  Urol Int       Date:  2021-05-31       Impact factor: 1.934

Review 7.  New therapeutic directions to treat underactive bladder.

Authors:  Toby C Chai; Tambudzai Kudze
Journal:  Investig Clin Urol       Date:  2017-12-19

Review 8.  The underactive bladder: diagnosis and surgical treatment options.

Authors:  Johan Gani; Derek Hennessey
Journal:  Transl Androl Urol       Date:  2017-07

9.  Clinical outcomes of sacral neuromodulation in non-neurogenic, non-obstructive dysuria: A 5-year retrospective, multicentre study in China.

Authors:  Ling-Feng Meng; Wei Zhang; Jian-Ye Wang; Yao-Guang Zhang; Peng Zhang; Li-Min Liao; Jian-Wei Lv; Qing Ling; Zhong-Qing Wei; Tie Zhong; Zhi-Hui Xu; Wei Wen; Jia-Yi Li; De-Yi Luo
Journal:  World J Clin Cases       Date:  2020-06-26       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.